• +1-646-491-9876
    • +91-20-67278686

    Search

    Restless Legs Syndrome - Pipeline Review, H1 2017

    Restless Legs Syndrome - Pipeline Review, H1 2017

    • Report Code ID: RW0001689373
    • Category Healthcare
    • No. of Pages 42
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

    Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf’s or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 1 respectively.

    Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Restless Legs Syndrome - Overview
    Restless Legs Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Restless Legs Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Restless Legs Syndrome - Companies Involved in Therapeutics Development
    Galenica Ltd
    Hisamitsu Pharmaceutical Co Inc
    Merz Pharma GmbH & Co KgaA
    Mundipharma International Ltd
    Omeros Corp
    Serina Therapeutics Inc
    Restless Legs Syndrome - Drug Profiles
    (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aplindore fumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ferric carboxymaltose - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    incobotulinumtoxin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-527 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ropinirole hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SER-214 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Restless Legs Syndrome - Dormant Projects
    Restless Legs Syndrome - Discontinued Products
    Restless Legs Syndrome - Product Development Milestones
    Featured News & Press Releases
    May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs
    Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome
    Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome
    Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
    Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome
    Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Restless Legs Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Restless Legs Syndrome - Pipeline by Galenica Ltd, H1 2017
    Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
    Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2017
    Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H1 2017
    Restless Legs Syndrome - Pipeline by Omeros Corp, H1 2017
    Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H1 2017
    Restless Legs Syndrome - Dormant Projects, H1 2017
    Restless Legs Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Restless Legs Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Galenica Ltd
    Hisamitsu Pharmaceutical Co Inc
    Merz Pharma GmbH & Co KgaA
    Mundipharma International Ltd
    Omeros Corp
    Serina Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//restless-legs-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//restless-legs-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//restless-legs-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments